0.97
-0.0094 (-0.96%)
-0.0094 (-0.96%)
Upgrade to Real-Time
Premarket
| Volume | 443 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Quince Therapeutics Inc | QNCX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0094 | -0.96% | 0.97 | 04:41:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.9794 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 443 | - | 0.5401 - 6.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:19:38 | formt | 342 | $ 0.97 | USD |
Period:
Draw Mode:
Quince Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 35.05M | 36.13M | 25.47M | $ - | $ - | -3.03 | -0.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -1.64k | 6.90% |
Quince Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QNCX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.91 | 1.09 | 0.91 | 0.9951498 | 462,843 | 0.06 | 6.59% |
| 1 Month | 0.7438 | 1.47 | 0.715 | 1.06 | 3,864,222 | 0.2262 | 30.41% |
| 3 Months | 0.7317 | 1.47 | 0.5401 | 1.02 | 1,433,834 | 0.2383 | 32.57% |
| 6 Months | 2.18 | 2.7171 | 0.5401 | 1.08 | 770,494 | -1.21 | -55.5% |
| 1 Year | 5.50 | 6.80 | 0.5401 | 2.07 | 620,315 | -4.53 | -82.36% |
| 3 Years | 50.72 | 121.98 | 0.5401 | 17.60 | 544,021 | -49.75 | -98.09% |
| 5 Years | 20.00 | 121.98 | 0.5401 | 18.70 | 457,179 | -19.03 | -95.15% |
Quince Therapeutics Description
| Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics. |
